Early data presented by Cassava Sciences demonstrates the safety of their Alzheimer’s drug simufilam, which is currently in Phase 3 clinical trials. But in late…
The biotechnology company Cassava Sciences — makers of simufilam, an anti-Alzheimer’s drug currently in Phase III clinical trials — was accused of scientific misconduct…
Whether it be coping with the cognitive, behavioral or psychological symptoms of dementia, adapting caregiver strategies throughout the different stages of the illness is…
Scientists in the field of Alzheimer’s have struggled to carry promising findings in mice studies into human trials, but primate researchers believe that animals…
Cassava Sciences revealed positive clinical data from their simufilam trial, a potentially disease-modifying therapy for treating Alzheimer’s. Their preliminary study showed that simufilam significantly…
UPDATE: 3 March 2024, 8:40 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…
Instead of developing a new drug from the ground up — a time-consuming and costly process — experts say that repurposing medications could accelerate…
UPDATE: 3 March 2024, 8:33 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Nearly every Alzheimer’s clinical trial has been deemed a failure, yet some participants have positively responded to experimental treatment. Now, scientists are developing predictive…
Biogen’s aducanumab — a human antibody-based drug that targets beta-amyloid plaques, which are found in the brains of people with Alzheimer’s — has gone…
Scientists are diversifying their approaches to finding an effective treatment for Alzheimer’s as clinical trials targeting beta-amyloid plaques, one of the hallmarks of the…
In 2013, Amylyx Pharmaceuticals co-founders Justin Klee and Josh Cohen, undergraduate students at Brown University at the time, hypothesized that targeting two dysfunctional pathways…
Developing a new drug start to finish can take years — even decades — and cost billions. But, there’s a shortcut: repurposing old drugs…
This weekend, Eli Lilly and Company presented detailed results of its phase 2 TRAILBLAZER-ALZ trial, showing that its investigational drug donanemab — monoclonal antibody…